Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2005-03-22
2005-03-22
Foley, Shanon (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S006120, C536S023720
Reexamination Certificate
active
06869759
ABSTRACT:
This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), particularly treatment regimens including a protease inhibitor. The invention further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy using phenotypic or genotypic susceptibility assays.
REFERENCES:
patent: 5436131 (1995-07-01), Condra et al.
patent: 5766842 (1998-06-01), Melnick et al.
patent: 5837464 (1998-11-01), Capon et al.
patent: 6033902 (2000-03-01), Haseltine et al.
patent: 6103462 (2000-08-01), Paulous et al.
patent: 6242187 (2001-06-01), Capon et al.
patent: 20020064838 (2002-05-01), Parkin et al.
patent: 20030108857 (2003-06-01), Parkin et al.
patent: 20040106106 (2004-06-01), Parkin et al.
patent: WO9967427 (1999-06-01), None
patent: PCTUS00/17178 (2000-12-01), None
patent: WO0078996 (2000-12-01), None
patent: WO0222076 (2002-03-01), None
patent: WO02068618 (2002-09-01), None
patent: WO02099387 (2002-12-01), None
patent: PCTUS02/18684 (2003-01-01), None
patent: WO03070700 (2003-08-01), None
patent: WO04003512 (2004-01-01), None
patent: WO04003514 (2004-01-01), None
patent: PCTUS03/21355 (2004-05-01), None
patent: PCTUS03/21023 (2004-07-01), None
patent: PCTUS03/04362 (2004-12-01), None
Patick et al. Antimicrobial Agents and Chemotherapy. 1998; 42 (10): 2637-2644.*
Carrillo et al., (1998), “In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants With Increased Resistance to ABT-378, a Novel Protease Inhibitor,”Journal of Virology,72(9):7532-41.
Condra et al., (1996), “Genetic Correlates of In Vivo Resistance to Indinavir, a Human Immnodeficiency Virus Type 1 Protease Inhibitor,”Journal of Virology,70(12): 8270-76.
Genbank Accession No. P12497 POL Polyprotein (2004).
Genbank Accession No. AF324493 HIV-1 vector pNL4 . . . [gi:1283114](2001).
Gervaix, et al., (1997), “A New Reporter Cell Line to Monitor HIV Infection and Drug Susceptibility in Vitro,”Proc. Natl. Acad. Sci. USA,94: 4653-4658.
Gong et al., (2000), “In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632,”Antimicrobial Agents and Chemotherapy,44(9):2319-26.
Gunthard, et al., (1998), “Comparative Performance of High-Density Oligonucleotide Sequencing and Dideoxynucleotide Sequencing of HIV Type 1 pol From Clinical Samples,”Aids Research and Human Retroviruses.14(10):869-876.
Haubrich et al., (2001), “CCTG 575: A Randomized, Prospective Study of Phenotype Testing Versus Standard of Care For Patients Failing Antiretroviral Therapy,”Antiviral Therapy,6(Supplement 1); 63.
Herrmann, et al., (1997), “A Working Hypotheses-Virus Resistance Development As An Indicator of Specific Antiviral Activity,”Ann. NY Acad Sciences,284:632-637.
Hirsch, et al., (2000), “Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection”,JAMA,283(18): 2417-26.
Katzenstein et al., (2002), “Baseline Phenotypic Susceptibility and Virologic failure over 144 weeks Among Nucleoside RT Experienced Subjects in ACTG 364, Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection,”2002 9thConference on Retroviruses and Opportunistic Infections,Session 77 Poster Session 591-T.
Katzenstein et al., (2002), “The Inhibitory Quotient (IQ) for Saquinavir (SQV) Predicts Virologic Response to Salvage Therapy,”2002 9thConference on Retroviruses and Opportunistic Infections,Session 28 Poster Session 129.
Kempf et al., (2001), “Identification of Genotypic Changes in Human Immunodeficiency Virus Protease that Correlate With Reduced Susceptibility to the Protease Inhibitor Lopinavir Among Viral Isolates From Protease Inhibitor-Experienced Patients,”Journal of Virology,75(16):7462-69.
Maguire et al., (2002), “Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadminstered Reverse Transcriptase Nucleoside Inhibitors,”Antimicrobial Agents and Chemotherapy,46(3): 731-738.
Petropoulos, et al., (2000), “A Novel Phenotypic Drug Susceptibility Assay For Human Immunodeficiency Virus Type 1,”Antimicrobial Agents and Chemotherapy,44(4): 920-928.
Race, et al., (1999), “Analysis of HIV Cross-Resistance to Protease Inhibitors Using A Rapid Single-Cycle Recombinant Virus Assay For Patients Failing On Combination Therapies,”AIDS,13(15):2061-2068.
Rusconi, Stefano. et al. (2000): “Susceptibility to PNU-140690 (Tipranavir) of Human Immunodeficiency Virus Type 1 Isolates Derived From Patients with Multidrug Resistance to Other Protease Inhibitors,”Antimicrobial Agents and Chemotherapy,44(5): 1328-32.
Schuurman, et al, (1999), “Worlwide Evaluation of DNA Sequencing Approaches for Identification of Drug Resistance Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase,”Journal of Clinical Microbiology,37(3):2291-2296.
Shi, et al., (1997), “A Recombinant Retroviral System for Rapid In Vivo Analysis of Human Immunodeficiency Virus Type 1 Susceptibility to Reverse Transcriptase Inhibitors,”Antimicrobial Agents and Chemotherapy,41(12): 2781-85.
Tisdale, M. et al. (1995): “Cross-Resistance Analysis of Human Immunodeficiency Virus Type 1 Variants Individually Selected for Resistance to Five Different Protease Inhibitors,”Antimicro. Agents and Chemo.39(8):1704-10.
Dreyer GB, et al. “A Symmetric Inhibitor Binds HIV-I Protease Asymmetrically”Biochemistry(1993) 32:937-947.
J. Eron, et al., Preliminary Assessment of 141 W94 in Combination with Other Protease Inhibitors,5th Conference on Retroviruses and Opportunistic Infections:(1995) 6.
Hill, A. et al., (1998) “Low frequency of genotypic mutations associated with resistance to AZT and 3TC after combination treatment with indinavar,”Int. Conf. AIDS12:812, (Abstract No. 6).
E. E. Kim, (1995) “Crystal Structure of HIV-1 Protease in Complex with VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme,”J. Am. Chem. Soc.,117:1181-1182.
Lambert DM, et al. (1992) “Human Immunodeficiency Virus Type I Protease Inhibitors Irreversibly Block Infectivity of Purified Virions From Chronically Infected Cells”Anti Microb Agents Chem36:982-98.
Brendan A. Larder, et al., (1995) “Potential Mechanism for; Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy,”Science,269; 696-699.
Janis K. Lazdins, et al., (1997) “In Vitro Effect of al-Acid Glycoprotein on the Anti-Human Immunodeficiency Virus (HIV) Activity of the Inhibitor CGP 61775: A Comparative Study wits Other Relevant HIV Protease Inhibitors,”J Infec. Dis.,175: 1063-1070.
David J. Livingston, et al., (1995) “Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Humar Immunodeficiency Virus Therapy,”J Infec. Dis.,172:1.238-124.
Bhuvaneshwari Mahalingam, et al., (1999) “Structural and Kinetic Analysis of Drug Resistant Mutants of HIV Protease,”Biochem.,263: 1-9.
Miller M, et al. (1989) Structure of Complex of Synthetic HIV-1j Protease with a SubstrateBased Inhibitor at 2.3 A Resolution,Science246:1149-1152.
Mohri H, et al. (1993) “Quantitation of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 in the Blood of Treated and Untreated Patients,”PNAS90:25-29.
Robert L. Murphy, et al., (1999) “Treatment with Amprenavir Alone or Amprenavir with Zidovudine and Lamivudine in Adults with Human Immunodeficiency Virus Infection”,J. Infec. Dis.,179:808-81 E.
Najera I, et al., (1994) “Natural Occurrecne of Drug ResistancE Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type
Parkin Neil T.
Ziermann Rainer A.
Foley Shanon
Jones Day
ViroLogic, Inc.
LandOfFree
Means and methods for monitoring protease inhibitor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Means and methods for monitoring protease inhibitor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Means and methods for monitoring protease inhibitor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3393045